A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Exemestane (Aromasin)

Aromatase Inhibitor class · 7 generic manufacturers · 7 ANDAs filed at FDA.

First FDA approval1999-10-21
Generic availableYes · 7 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$46.3M in CY2024 Part D spend339K claims · 103K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.593/unit
10 NDCs benchmarked, lowest of all strengths.
Average NADAC
$4.43
Across all dosage forms in distribution.
Highest NADAC
$38.98
Wide spread — brand-strength NDCs still in market.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Exemestane used for?

Exemestane is a Aromatase Inhibitor medication tracked in Medicare Part D.

Is there a generic for Exemestane?

Yes. 7 ANDAs filed at FDA, 7 generic manufacturers currently shipping.

How much does my plan pay for Exemestane?

Across 329 Part D plans, Exemestane averages $4.43/unit (NADAC). Lowest available: $0.593/unit. Highest in distribution: $38.98/unit.

Is Exemestane on the FDA shortage list?

No. Exemestane is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Aromatase Inhibitor4 alternatives in D1
01
Anastrozole
Brand: ARIMIDEX
$0.139Lowest NADAC
8Generic mfrs
$54.5MCY24 Part D spend
Compare →
02
Anastrozole Tablets
Brand: Anastrozole
$0.139Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Letrozole
Brand: Femara
$0.146Lowest NADAC
5Generic mfrs
$31.7MCY24 Part D spend
Compare →
04
Letrozole Tablets
Brand: Letrozole
$0.146Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (8 approvals on file) · NADAC unit costs: CMS NADAC weekly file (10 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.